Source - SMW
Hemodynamic monitoring company LiDCO said that its latest cardiac output monitor with non-invasive technology had received regulatory approval for commercial sale in China.

The Chinese Food and Drug Administration formally approved the company's hemodynamic LiDCOrapidv3 monitor product.

It would be sold via LiDCO's distribution partner, Beijing Gloryway Medical, a medical device sales group specialising in anaesthesia and patient monitoring.


At 1:57pm: (LON:LID) LiDCO Group PLC share price was +0.65p at 5.1p



Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.